These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21386839)

  • 1. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
    Bertolini F; Malavasi N; Scarabelli L; Fiocchi F; Bagni B; Del Giovane C; Colucci G; Gerunda GE; Depenni R; Zironi S; Fontana A; Pettorelli E; Luppi G; Conte PF
    Br J Cancer; 2011 Mar; 104(7):1079-84. PubMed ID: 21386839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
    Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
    Mertens J; De Bruyne S; Van Damme N; Smeets P; Ceelen W; Troisi R; Laurent S; Geboes K; Peeters M; Goethals I; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1214-22. PubMed ID: 23636802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
    Takahashi T; Shibata Y; Tojima Y; Tsuboi K; Sakamoto E; Kunieda K; Matsuoka H; Suzumura K; Sato M; Naganuma T; Sakamoto J; Morita S; Kondo K
    Int J Clin Oncol; 2013 Apr; 18(2):335-42. PubMed ID: 22383023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
    J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
    Emmanouilides C; Sfakiotaki G; Androulakis N; Kalbakis K; Christophylakis C; Kalykaki A; Vamvakas L; Kotsakis A; Agelaki S; Diamandidou E; Touroutoglou N; Chatzidakis A; Georgoulias V; Mavroudis D; Souglakos J
    BMC Cancer; 2007 May; 7():91. PubMed ID: 17537235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
    Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
    Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
    Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
    Nasti G; Piccirillo MC; Izzo F; Ottaiano A; Albino V; Delrio P; Romano C; Giordano P; Lastoria S; Caracò C; de Lutio di Castelguidone E; Palaia R; Daniele G; Aloj L; Romano G; Iaffaioli RV
    Br J Cancer; 2013 Apr; 108(8):1566-70. PubMed ID: 23558891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.